Canopy Growth (NASDAQ:CGC) Stock Price Down 3.8% - Here's What Happened

Key Points

• Canopy Growth shares fell 3.8% intraday to $1.625 on Friday with about 13.98 million shares traded (roughly 18% below average) after a $1.69 close.
• President Trump’s executive order to reclassify marijuana toward Schedule III is seen as a major structural positive for the cannabis sector — potentially easing banking, research and CBD access — and has generated bullish analyst commentary.
• Despite the policy tailwind, investors rotated out of CGC into U.S. operators and took profits amid concerns over the company’s weak fundamentals (market cap ≈ $565.6M, negative EPS and margins) and mixed analyst ratings (MarketBeat average: "Reduce").

Canopy Growth Corporation (NASDAQ:CGC - Get Free Report) shares fell 3.8% during trading on Friday . The company traded as low as $1.63 and last traded at $1.6250. 13,981,633 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 17,032,730 shares. The stock had previously closed at $1.69.

More Canopy Growth News

Here are the key news stories impacting Canopy Growth this week:

• Positive Sentiment: Trump signed an executive order to reclassify marijuana toward Schedule III, which could reduce regulatory friction, improve banking/insurance access and broaden research and CBD availability — a major structural positive for cannabis companies. President Trump Signs Cannabis Executive Order: Canopy Growth Collapses
• Positive Sentiment: Mainstream outlets emphasize the policy shift as near-term sentiment fuel for the sector — easier federal research, potential tax and regulatory relief and improved consumer access. (Multiple coverage: CNBC, Reuters, Business Insider, Zacks). Trump signs executive order reclassifying pot, opening door to broader access
• Positive Sentiment: Zacks and analyst commentary note rescheduling to Schedule III could reshape regulation and taxation for the sector, boosting long-term earnings potential for well-positioned firms. Trump Orders Marijuana Reclassification: What It Means for the Sector
• Positive Sentiment: Roth MKM reiterated a buy rating on Canopy Growth — supporting a bullish analyst view even after recent gains. That may limit downside for longer-term investors. Roth MKM Sticks to Their Buy Rating for Canopy Growth (CGC)
• Positive Sentiment: Several analyst pieces and investor write-ups highlight upside after the rally, with some calling for further gains — evidence of continuing bullish consensus despite volatility. Canopy Growth Is Surging and Analysts Still Think It Can Gain 40% from Here
• Neutral Sentiment: Coverage explaining consumer implications and CBD access is informative but ambiguous in timing — benefits are structural but may take months to implement through the DOJ and FDA. Trump moves to ease cannabis restrictions - what does it mean for consumers?
• Negative Sentiment: Despite the sector-positive headlines, some outlets highlight an immediate sell-off in Canopy shares — investors likely took profits after a big run, rotated to U.S. operators who may gain more from rescheduling, and reacted to CGC’s still-weak profitability metrics. High trading volume reinforces that this was active rebalancing rather than a one-off trade. President Trump Signs Cannabis Executive Order: Canopy Growth Collapses

Analyst Ratings Changes

CGC has been the topic of several recent analyst reports. Benchmark upgraded shares of Canopy Growth from a "sell" rating to a "hold" rating in a research note on Monday, November 10th. Alliance Global Partners restated a "neutral" rating on shares of Canopy Growth in a report on Monday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Canopy Growth in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Canopy Growth from a "sell" rating to a "hold" rating in a research note on Saturday, November 8th. Three equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce".

Canopy Growth Stock Down 9.2%

The business's fifty day moving average price is $1.26 and its 200 day moving average price is $1.31. The firm has a market capitalization of $565.58 million, a price-to-earnings ratio of -0.80 and a beta of 0.40. The company has a current ratio of 5.50, a quick ratio of 4.23 and a debt-to-equity ratio of 0.31.

Canopy Growth (NASDAQ:CGC - Get Free Report) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.10. The firm had revenue of $47.86 million during the quarter, compared to analysts' expectations of $71.82 million. Canopy Growth had a negative net margin of 113.21% and a negative return on equity of 61.97%. On average, equities analysts expect that Canopy Growth Corporation will post -2.81 EPS for the current year.

Insider Activity

In related news, CEO Luc Mongeau purchased 27,469 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The shares were purchased at an average price of $1.82 per share, for a total transaction of $49,993.58. Following the transaction, the chief executive officer directly owned 812,368 shares of the company's stock, valued at approximately $1,478,509.76. The trade was a 3.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 23,075 shares of company stock worth $36,459 over the last 90 days. Company insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Boothbay Fund Management LLC purchased a new stake in shares of Canopy Growth during the second quarter worth approximately $30,000. Midwest Trust Co acquired a new position in Canopy Growth in the 3rd quarter valued at $31,000. Wealth Enhancement Advisory Services LLC raised its position in Canopy Growth by 81.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 32,336 shares of the company's stock worth $41,000 after buying an additional 14,498 shares during the last quarter. Genesee Capital Advisors LLC lifted its stake in shares of Canopy Growth by 166.1% in the 3rd quarter. Genesee Capital Advisors LLC now owns 40,047 shares of the company's stock worth $58,000 after acquiring an additional 25,000 shares during the period. Finally, Insigneo Advisory Services LLC increased its stake in shares of Canopy Growth by 168.7% during the third quarter. Insigneo Advisory Services LLC now owns 43,001 shares of the company's stock worth $63,000 after acquiring an additional 27,000 shares during the period. 3.33% of the stock is currently owned by hedge funds and other institutional investors.

About Canopy Growth

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.